Meeting
2018 ASCO Annual Meeting
NRG BN002: Phase I study of checkpoint inhibitors anti-CTLA-4, anti-PD-1, the combination in patients with newly diagnosed glioblastoma.
Authors
Andrew E. Sloan
University Hospital Case Medical Center, Cleveland, OH
Andrew E. Sloan , Mark R. Gilbert , Peixin Zhang , Kenneth D. Aldape , Jing Wu , Lisa R. Rogers , Patrick Y. Wen , Igor J. Barani , Fabio Massaiti Iwamoto , Raju R. Raval , Alfredo Daniel Voloschin , John Frederick De Groot , Minhee Won , Minesh P. Mehta
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT02311920
Citation
J Clin Oncol 36, 2018 (suppl; abstr 2053)
DOI
10.1200/JCO.2018.36.15_suppl.2053
Abstract #
2053
Poster Bd #
211
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM).
First Author: John Howard Sampson
Poster
2013 ASCO Annual Meeting
Phase I adult brain tumor consortium (ABTC) trial of ABT-888 (veliparib), temozolomide (TMZ), and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM) including pharmacokinetic (PK) data.
First Author: Lawrence Kleinberg
Poster
2019 ASCO Annual Meeting
A TITE-CRM phase I/II study of disulfiram and copper with concurrent radiation therapy and temozolomide for newly diagnosed glioblastoma.
First Author: Jiayi Huang
Poster
2017 ASCO Annual Meeting
Nivolumab (nivo) + nab-paclitaxel (nab-P) + carboplatin (C) in patients (pts) with non-small cell lung cancer (NSCLC): Interim results from a multicenter phase I study.
First Author: David Michael Waterhouse